Patient-tailored medicine, part two: personalized medicine and the legal landscape.
In Part One, the authors addressed the relevance of genetic information, and how race and genetics have affected and may impact the development of medicines, pharmacogenomics, and personalized medicine in the United States. Part Two examines current and proposed federal and state laws and regulations intended to protect individuals from the misuse of genetic information, including uses that discriminate based on genetic predispositions. This Part next explores the potential for litigation against both manufacturers and providers,as well as potential defenses. The authors also discuss legal issues relating to research that relies on the use of genetic information.
Braff
Jeffrey P
JP
Kaiser Permanente, USA. jeff.braff@kp.org
Chatterjee
Biswajit
B
Hochman
Meredith
M
Kennington
Jessica
J
Kolavala
Chandana
C
Layman
Katherine
K
Parver
Corrine
C
Rice
Chelsea S
CS
Selby
Myra C
MC
Washlick
John R
JR
Wolf
Rebecca
R
D003219:Confidentiality / Q000331:legislation & jurisprudence*; D035082:Federal Government; D030661:Genetic Privacy / Q000331:legislation & jurisprudence*; D005820:Genetic Testing / Q000331:legislation & jurisprudence; D020408:Health Insurance Portability and Accountability Act; D006801:Humans; D019451:Information Management / Q000331:legislation & jurisprudence; D007880:Legislation, Drug; D016365:Liability, Legal; D014481:United States